{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T20:08:51Z","timestamp":1787947731007,"version":"build-2784847793"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T00:00:00Z","timestamp":1745798400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T00:00:00Z","timestamp":1745798400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007051","name":"Uppsala University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007051","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Potassium binders mitigate hyperkalemia, allowing patients to maintain their renin-angiotensin-aldosterone-system inhibitor (RAASi) treatment. This study characterized patients treated with first- or second-generation potassium binders, usage patterns and their effectiveness in reducing potassium levels, and changes in RAASi treatment in a Swedish population-based study.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A <jats:italic>National Cohort<\/jats:italic> included patients who had record of a treatment episode with a first-generation or second-generation potassium binder between 2018 and 2022. A <jats:italic>Mid-Sweden Cohort<\/jats:italic> included patients from the <jats:italic>National Cohort<\/jats:italic> who also had a record of a potassium measurement within the 60 days prior to beginning potassium binder treatment. Comorbidities, prior medication use, persistence with potassium binder treatment, subsequent changes in potassium levels and RAASi treatment were evaluated. Persistence was analyzed using the Kaplan-Meier estimator and changes in potassium levels were assessed using linear mixed-effects models.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>23,892 treatment episodes involving 14,235 patients (mean age 70 years, 33% women) were followed in the <jats:italic>National Cohort<\/jats:italic>, and 4860 episodes involving 3179 patients (mean age 72 years, 34% women) in the <jats:italic>Mid-Sweden Cohort<\/jats:italic>. Patients treated with second-generation potassium binders had more comorbidities and higher median persistence with treatment compared to those on first-generation potassium binders, 112.5 (95% CI:112.5-117.5) vs. 87.5 (95% CI: 87.5\u201387.5) days in the <jats:italic>National Cohort<\/jats:italic>; 165.5 (95% CI: 121.0-198.0) vs. 97.6 (95% CI: 87.5\u2013110.0) days in the <jats:italic>Mid-Sweden Cohort<\/jats:italic>. Both first- and second-generation potassium binders reduced potassium levels from baseline by day 15, 5.7 [95% CI: 4.5\u20136.8] mmol\/L to 4.7 [95% CI: 3.6\u20135.9] mmol\/L and 5.5 (95% CI: 4.3\u20136.7) mmol\/L to 4.9 (95% CI: 3.8\u20136.1) mmol\/L, respectively. Dose reduction or discontinuation of renin-angiotensin system inhibitors (RASi) or mineralocorticoid receptor antagonists (MRAs) was found in 31.4% and 47.7%, respectively, within 120 days of initiating therapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Both potassium binders effectively reduced potassium levels, but frequent discontinuation or dose reduction of RAASi therapy were still observed during this period. The adjustments of RAASi therapy, despite the achievement of normokalemia within 15 days, may be premature and warrants careful reconsideration to ensure optimal patient outcomes.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12882-025-04146-8","type":"journal-article","created":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T07:04:44Z","timestamp":1745823884000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Potassium binders in clinical practice: understanding potassium binder use in contemporary Swedish healthcare\u2014the DEMONSTRATE database"],"prefix":"10.1186","volume":"26","author":[{"given":"Hans","family":"Furuland","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders Olof","family":"Larsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Bjellerup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milica","family":"Uhde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Cars","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matilda","family":"Almstedt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria K.","family":"Svensson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,28]]},"reference":[{"issue":"4","key":"4146_CR1","doi-asserted-by":"publisher","first-page":"e074064","DOI":"10.1136\/bmjopen-2023-074064","volume":"14","author":"J Sundstr\u00f6m","year":"2024","unstructured":"Sundstr\u00f6m J, Norhammar A, Karayiannides S, Bodeg\u00e5rd J, Gustafsson S, Cars T, et al. Are there lost opportunities in chronic kidney disease? A region-wide cohort study. BMJ Open. 2024;14(4):e074064.","journal-title":"BMJ Open"},{"issue":"7","key":"4146_CR2","doi-asserted-by":"publisher","first-page":"e005428","DOI":"10.1161\/JAHA.116.005428","volume":"6","author":"G Bandak","year":"2017","unstructured":"Bandak G, Sang Y, Gasparini A, Chang AR, Ballew SH, Evans M, et al. Hyperkalemia after initiating Renin-Angiotensin system Blockade: the Stockholm creatinine measurements (SCREAM) project. J Am Heart Assoc. 2017;6(7):e005428.","journal-title":"J Am Heart Assoc"},{"issue":"6","key":"4146_CR3","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1161\/HYPERTENSIONAHA.116.07363","volume":"67","author":"AR Chang","year":"2016","unstructured":"Chang AR, Sang Y, Leddy J, Yahya T, Kirchner HL, Inker LA, et al. Antihypertensive medications and the prevalence of hyperkalemia in a large health system. Hypertension. 2016;67(6):1181\u20138.","journal-title":"Hypertension"},{"key":"4146_CR4","doi-asserted-by":"publisher","first-page":"105835","DOI":"10.1016\/j.phrs.2021.105835","volume":"172","author":"GL Hundemer","year":"2021","unstructured":"Hundemer GL, Sood MM. Hyperkalemia with RAAS Inhibition: mechanism, clinical significance, and management. Pharmacol Res. 2021;172:105835.","journal-title":"Pharmacol Res"},{"key":"4146_CR5","doi-asserted-by":"crossref","unstructured":"Linde C, Bakhai A, Furuland H, Evans M, McEwan P, Ayoubkhani D et al. Real-World associations of Renin\u2013Angiotensin\u2013Aldosterone system inhibitor dose, hyperkalemia, and adverse clinical outcomes in a cohort of patients with New-Onset chronic kidney disease or heart failure in the united Kingdom. J Am Heart Assoc. 2019;8(22).","DOI":"10.1161\/JAHA.119.012655"},{"issue":"3","key":"4146_CR6","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa1410853","volume":"372","author":"MR Weir","year":"2015","unstructured":"Weir MR, Bakris GL, Bushinsky DA, Mayo MR, Garza D, Stasiv Y, et al. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med. 2015;372(3):211\u201321.","journal-title":"N Engl J Med"},{"issue":"6","key":"4146_CR7","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1038\/ki.2015.270","volume":"88","author":"DA Bushinsky","year":"2015","unstructured":"Bushinsky DA, Williams GH, Pitt B, Weir MR, Freeman MW, Garza D, et al. Patiromer induces rapid and sustained potassium Lowering in patients with chronic kidney disease and hyperkalemia. Kidney Int. 2015;88(6):1427\u201333.","journal-title":"Kidney Int"},{"issue":"10208","key":"4146_CR8","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/S0140-6736(19)32135-X","volume":"394","author":"R Agarwal","year":"2019","unstructured":"Agarwal R, Rossignol P, Romero A, Garza D, Mayo MR, Warren S, et al. Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet. 2019;394(10208):1540\u201350.","journal-title":"Lancet"},{"issue":"12","key":"4146_CR9","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.2215\/CJN.03640415","volume":"10","author":"L Lepage","year":"2015","unstructured":"Lepage L, Dufour AC, Doiron J, Handfield K, Desforges K, Bell R, et al. Randomized clinical trial of sodium polystyrene sulfonate for the treatment of mild hyperkalemia in CKD. Clin J Am Soc Nephrol. 2015;10(12):2136\u201342.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"4146_CR10","first-page":"54","volume":"7","author":"F Zannad","year":"2020","unstructured":"Zannad F, Hsu BG, Maeda Y, Shin SK, Vishneva EM, Rensfeldt M, et al. Efficacy and safety of sodium zirconium cyclosilicate for hyperkalaemia: the randomized, placebo-controlled HARMONIZE-Global study. ESC Heart Fail. 2020;7(1):54\u201364.","journal-title":"ESC Heart Fail"},{"issue":"41","key":"4146_CR11","doi-asserted-by":"publisher","first-page":"4362","DOI":"10.1093\/eurheartj\/ehac401","volume":"43","author":"J Butler","year":"2022","unstructured":"Butler J, Anker SD, Lund LH, Coats AJS, Filippatos G, Siddiqi TJ, et al. Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial. Eur Heart J. 2022;43(41):4362\u201373.","journal-title":"Eur Heart J"},{"issue":"2","key":"4146_CR12","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1001\/jama.2015.7446","volume":"314","author":"GL Bakris","year":"2015","unstructured":"Bakris GL, Pitt B, Weir MR, Freeman MW, Mayo MR, Garza D, et al. Effect of patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease: the AMETHYST-DN randomized clinical trial. JAMA. 2015;314(2):151\u201361.","journal-title":"JAMA"},{"issue":"1","key":"4146_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1056\/NEJMp1411430","volume":"372","author":"A Anell","year":"2015","unstructured":"Anell A. The public-private pendulum\u2013patient choice and equity in Sweden. N Engl J Med. 2015;372(1):1\u20134.","journal-title":"N Engl J Med"},{"issue":"4","key":"4146_CR14","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1007\/s40620-023-01860-0","volume":"37","author":"A Gonzalez-Ortiz","year":"2024","unstructured":"Gonzalez-Ortiz A, Clase CM, Bosi A, Fu EL, P\u00e9rez-Guill\u00e9 BE, Faucon AL, et al. Evaluation of the introduction of novel potassium binders in routine care; the Stockholm creatinine measurements (SCREAM) project. J Nephrol. 2024;37(4):961\u201372.","journal-title":"J Nephrol"},{"key":"4146_CR15","doi-asserted-by":"publisher","unstructured":"Baumgartner PC, Haynes RB, Hersberger KE, Arnet I. A systematic review of medication adherence thresholds dependent of clinical outcomes. Front Pharmacol [Internet]. 2018 Nov 20 [cited 2024 Sep 17];9. Available from: https:\/\/www.frontiersin.org\/journals\/pharmacology\/articles\/https:\/\/doi.org\/10.3389\/fphar.2018.01290\/full","DOI":"10.3389\/fphar.2018.01290\/full"},{"key":"4146_CR16","doi-asserted-by":"crossref","unstructured":"Palmer P BF, Carrero JJ, Clegg DJ, Colbert GB, Emmett M, Fishbane S, et al. Clinical management of hyperkalemia. Mayo Clin Proc. 2021;96(3):744\u201362.","DOI":"10.1016\/j.mayocp.2020.06.014"},{"key":"4146_CR17","doi-asserted-by":"publisher","unstructured":"Holleck JL, Han L, Skanderson M, Bastian LA, Gunderson CG, Brandt CA et al. Risk of serious adverse gastrointestinal events with potassium binders in hospitalized patients: a national study. J Gen Intern Med [Internet]. 2024 Aug 5 [cited 2025 Feb 24]; Available from: https:\/\/link.springer.com\/https:\/\/doi.org\/10.1007\/s11606-024-08979-1","DOI":"10.1007\/s11606-024-08979-1"},{"issue":"8","key":"4146_CR18","doi-asserted-by":"publisher","first-page":"489","DOI":"10.12788\/jhm.3655","volume":"16","author":"JL Holleck","year":"2021","unstructured":"Holleck JL, Roberts AE, Marhoffer EA, Grimshaw AA, Gunderson CG. Risk of intestinal necrosis with sodium polystyrene sulfonate: A systematic review and Meta-analysis. J Hosp Med. 2021;16(8):489\u201394.","journal-title":"J Hosp Med"},{"issue":"3","key":"4146_CR19","doi-asserted-by":"publisher","first-page":"365","DOI":"10.2215\/CJN.12990820","volume":"16","author":"GL Hundemer","year":"2021","unstructured":"Hundemer GL, Talarico R, Tangri N, Leon SJ, Bota SE, Rhodes E, et al. Ambulatory treatments for RAAS Inhibitor\u2013Related hyperkalemia and the 1-Year risk of recurrence. Clin J Am Soc Nephrol. 2021;16(3):365.","journal-title":"Clin J Am Soc Nephrol"},{"key":"4146_CR20","doi-asserted-by":"publisher","first-page":"100438","DOI":"10.1016\/j.lanepe.2022.100438","volume":"20","author":"J Sundstr\u00f6m","year":"2022","unstructured":"Sundstr\u00f6m J, Bodegard J, Bollmann A, Vervloet MG, Mark PB, Karasik A, et al. Prevalence, outcomes, and cost of chronic kidney disease in a contemporary population of 2\u00b74 million patients from 11 countries: the careme CKD study. Lancet Reg Health Eur. 2022;20:100438.","journal-title":"Lancet Reg Health Eur"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04146-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-025-04146-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04146-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T07:04:47Z","timestamp":1745823887000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-025-04146-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,28]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4146"],"URL":"https:\/\/doi.org\/10.1186\/s12882-025-04146-8","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,28]]},"assertion":[{"value":"18 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and was approved by the Swedish Ethical Review Authority (approval number 2022-01051-01 and 2022-06306-02). All data used in the study were secondary data that was pseudonymized, and presented on an aggregated level ensuring that no individual can be identified. Given the nature of the study, informed consent was not required by Swedish Ethical Review Authority.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"HF has received consultancy fees from AstraZeneca, GSK, Vifor Pharma Nordiska AB, Bayer and Amgen. MKS has received honoraria from Amgen, AstraZeneca, Boehringer Ingelheim, GSK, NovoNordisk and Vifor Pharma Nordiska AB. AOL has received consultancy fees from Vifor Pharma Nordiska AB. TC and MA are employees at Sence Research AB, which is a company in biostatistics and epidemiology that received payment from Vifor Pharma Nordiska AB for project management, data management and statistical analysis during the conduct of the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"213"}}